Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chiyuki Kokan"'
Publikováno v:
Thoracic Cancer, Vol 12, Iss 6, Pp 746-751 (2021)
Abstract Background Indication for treatment with osimertinib after first/second generation (1/2G) epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) resistance depends on T790M mutation detected by rebiopsy. The aim of our stu
Externí odkaz:
https://doaj.org/article/ff2967f0561b419b97e11db5a19ced6c
Autor:
Chiyuki Kokan, Nobuyuki Katakami, Shoji Fukushima, Yutaka Okada, Akito Hata, Reiko Kaji, Kei Irie, Akira Okada, Nobuyuki Sugioka, Yuta Yamasaki, Keizo Fukushima
Publikováno v:
Therapeutic Drug Monitoring. 40:716-724
Background Nivolumab is a fully humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor, disrupting PD-1-mediated signaling and restoring antitumor immunity. The objective of this study was to develop a nivolumab quanti
Autor:
Miyako Satouchi, Ken Uchibori, Motoko Tachihara, Chiyuki Kokan, Yoshiko Urata, Keisuke Aoe, Kazuyuki Kobayashi, Kentaro Iwanaga, Akemi Sato, Naoko Sueoka-Aragane, Satoshi Morita, Tomonori Hirashima, Nobuyuki Katakami, Shunichi Negoro, Takako Inoue, Fumio Imamura, Masahide Mori
Publikováno v:
Lung Cancer. 124:65-70
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression caused by acquir
Autor:
Nobuyuki Katakami, Shigeki Nanjo, Reiko Kaji, Yutaka Okada, Shoji Fukushima, Shiro Fujita, Chiyuki Kokan, Kei Irie, Katsuhiro Masago, Akito Hata
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO2-14
Autor:
Shoji Fukushima, Katsuhiro Masago, Kei Irie, Akito Hata, Seika Hiratsuji, Chiyuki Kokan, Reiko Kaji, Yuta Yamasaki, Yutaka Okada, Shigeki Nanjo, Shiro Fujita, Nobuyuki Katakami, Saori Shobu
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of gefitinib in dried blood spots (DBSs). Gefitinib was extracted with methanol from DBS of 3 mm in diameter and detected using a tr
Autor:
Kei Irie, Akira Okada, Yuta Yamasaki, Chiyuki Kokan, Akito Hata, Reiko Kaji, Keizo Fukushima, Nobuyuki Sugioka, Yutaka Okada, Nobuyuki Katakami, Shoji Fukushima
Publikováno v:
Therapeutic Drug Monitoring; Dec2018, Vol. 40 Issue 6, p716-724, 9p